Moreover, they also reported that HPCs derived from a less- and a more-advanced disease stage of MDS/AML-iPSCs displayed different responses to rigosertib, a small molecule inhibitor of RAS signaling currently undergoing clinical trials for high-risk MDS, with the KRAS-mutated line being more responsive to the treatment [134]. This evidence concerns the gene KRAS and myelodysplastic syndrome.